BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32761250)

  • 1. Enhanced Cellular Uptake and Gene Silencing Activity of Survivin-siRNA via Ultrasound-Mediated Nanobubbles in Lung Cancer Cells.
    Akbaba H; Erel-Akbaba G; Kotmakçı M; Başpınar Y
    Pharm Res; 2020 Aug; 37(8):165. PubMed ID: 32761250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.
    Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W
    Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
    Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
    Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GABA
    Ni S; Liu Y; Tang Y; Chen J; Li S; Pu J; Han L
    Carbohydr Polym; 2018 Jan; 179():135-144. PubMed ID: 29111036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.
    Wang J; Lu Z; Wang J; Cui M; Yeung BZ; Cole DJ; Wientjes MG; Au JL
    J Control Release; 2015 Oct; 216():103-10. PubMed ID: 26272765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
    Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
    Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis.
    Chen X; Zhang Y; Tang C; Tian C; Sun Q; Su Z; Xue L; Yin Y; Ju C; Zhang C
    Int J Pharm; 2017 Aug; 529(1-2):102-115. PubMed ID: 28642204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of nanobubbles containing paclitaxel and survivin inhibitor YM155 against lung cancer.
    Başpınar Y; Erel-Akbaba G; Kotmakçı M; Akbaba H
    Int J Pharm; 2019 Jul; 566():149-156. PubMed ID: 31129344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasound-mediated PLGA-PEI Nanobubbles Carrying STAT6 SiRNA Enhances NSCLC Treatment
    Shu H; Lv W; Ren ZJ; Li H; Dong T; Zhang Y; Nie F
    Curr Drug Deliv; 2024; 21(8):1114-1127. PubMed ID: 37491853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.
    Yu H; Xu Z; Chen X; Xu L; Yin Q; Zhang Z; Li Y
    Macromol Biosci; 2014 Jan; 14(1):100-9. PubMed ID: 23966347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.
    Mattheolabakis G; Ling D; Ahmad G; Amiji M
    Pharm Res; 2016 Dec; 33(12):2943-2953. PubMed ID: 27528390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective combination treatment of lung cancer cells by single vehicular delivery of siRNA and different anticancer drugs.
    Li J; Wang Y; Xue S; Sun J; Zhang W; Hu P; Ji L; Mao Z
    Int J Nanomedicine; 2016; 11():4609-4624. PubMed ID: 27695321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes.
    Yin T; Wang P; Li J; Wang Y; Zheng B; Zheng R; Cheng D; Shuai X
    Biomaterials; 2014 Jul; 35(22):5932-43. PubMed ID: 24746965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
    Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
    Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation Of Nanobubbles Modified With A Small-Molecule CXCR4 Antagonist For Targeted Drug Delivery To Tumors And Enhanced Ultrasound Molecular Imaging.
    Peng Y; Zhu L; Wang L; Liu Y; Fang K; Lan M; Shen D; Liu D; Yu Z; Guo Y
    Int J Nanomedicine; 2019; 14():9139-9157. PubMed ID: 32063704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.
    Patil YB; Swaminathan SK; Sadhukha T; Ma L; Panyam J
    Biomaterials; 2010 Jan; 31(2):358-65. PubMed ID: 19800114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin-mediated inhibition of survivin increases sensitivity of head and neck squamous cell carcinoma cell lines to paclitaxel.
    Khan Z; Khan N; Varma AK; Tiwari RP; Mouhamad S; Prasad GB; Bisen P
    Curr Cancer Drug Targets; 2010 Nov; 10(7):660-9. PubMed ID: 20578991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of survivin and cyclin B1 through siRNA-loaded arginine modified calcium phosphate nanoparticles for non-small-cell lung cancer therapy.
    Kara G; Parlar A; Cakmak MC; Cokol M; Denkbas EB; Bakan F
    Colloids Surf B Biointerfaces; 2020 Dec; 196():111340. PubMed ID: 32956996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line.
    Montazeri Aliabadi H; Landry B; Mahdipoor P; Uludağ H
    Mol Pharm; 2011 Oct; 8(5):1821-30. PubMed ID: 21838308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer.
    Salzano G; Riehle R; Navarro G; Perche F; De Rosa G; Torchilin VP
    Cancer Lett; 2014 Feb; 343(2):224-31. PubMed ID: 24099916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.